Topical AS101 for Treatment of FAGA (Female Androgenetic Alopecia) in Menopause Women

Clalit Health Services

Status and phase: Unknown; Phase 2

Conditions: Alopecia

Treatments: Drug: AS101

Study type: Interventional

Funder types: Other

Identifiers

NCT00418249

#69 REV 00

Details and patient eligibility

About

The primary objective of this study is to assess the safety and efficacy of topical AS101 as treatment for Female Androgenetic Alopecia (FAGA) in menopause women.

Sex: Female

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Women in menopause, over 50 years of age.
• Clinically diagnosed for AGA, according to Ludwig scale I-II.

Exclusion criteria

• Women treated with chronic medications.
• Use of Minoxidil within 3 months prior to entering study.
• Women who have underwent hair transplantation.
• Use of drugs with androgenic or anti-androgenic effects.
• Any other type of hair loss.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind